Recall: Atovaquone
Apr. 2023Pharmacy Updates
Camber Pharmaceuticals Inc. is recalling Atovaquone Oral Suspension, USP 750 mg/5 mL, lot #E220182 with an expiration date of 12/2023, due to possible bacterial contamination in the product. This drug is used for the prevention and treatment of a lung infection called Pneumocystis jiroveci pneumonia (PCP) in adults and children 13 years old and older who cannot tolerate other medicines, such as trimethoprim-sulfamethoxazole. Read the full text of the Atovaquone recall.
Recent Announcements
Fostering Trust in Vaccinations Through Shared Decision Making
Please join us for a live, CME-accredited webinar on Thursday, September 11, from noon to 1 p.m. that will provide an overview of fostering trust in vaccinations through shared decision making.May 2025Education/Webinars
Pause in Prior Authorization Policies
On April 1, 2025, we announced that UPMC Health Plan would start requiring prior authorization for certain services. Please note that we are delaying or changing the implementation of prior authorization for some of these services, as described below.May 2025Important Notices
May is Mental Health Awareness Month
“Turn Awareness into Action”Mental Health America founded Mental Health Month in 1949, and since that time, every May has been a time to unite millions of people to promote awareness, provide vital resources, and advocate for everyones mental well-being. 1 in 5 people will experience a mental health condition in any given year¹. Mental health affects us all, and its critical that we move beyond awareness to take meaningful steps for our well-being and that of our community.May 2025Important Notices